New hope for advanced cancer patients after standard treatments fail
NCT ID NCT05522868
Summary
This early-stage trial is testing a new drug called SB17170 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest and most effective dose and to check for early signs that the drug might help shrink tumors. About 50 participants will receive the drug and be closely monitored for side effects and how their bodies process the medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
NOT_YET_RECRUITINGSeoul, South Korea
Contact
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, South Korea
Contact
-
Severance Hospital
RECRUITINGSeoul, South Korea
Contact
Conditions
Explore the condition pages connected to this study.